Compare Sibanye Stillwater Ltd (SBSW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Sanofi SA — how do they compare? Sibanye Stillwater Ltd trades at $10.03 (market cap $6.88B), while Sanofi SA trades at $40.14 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 13.8× Sibanye Stillwater Ltd's market cap, and Sibanye Stillwater Ltd pays the higher dividend (8.17%). Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and Sanofi SA for 94 Days on average.
| SBSW | SNY | |
|---|---|---|
Market Cap | $6.88B | $95.18B |
Volume | 4,474,536 | 2,995,646 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $52.34 |
52-Week Low | $8.00 | $39.51 |
Typical Hold Time | 51 Days | 94 Days |
Enterprise Value | $7.78B | $114.48B |
Dividend Yield | 8.17% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $9.99, up 3.2% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong operational improvement with 2025 revenue reaching $129.68B and positive net cash flow of $1.13B, though it posted a net loss of $5.17B. Recent Q2 2026 earnings beat expectations with $1.34 EPS versus $1.26 expected, indicating potential turnaround momentum. Analyst consensus remains positive with a $14.25 price target representing 43% upside potential from current levels.
The stock presents a compelling value opportunity with attractive valuation multiples (P/E 8.12, P/S 0.7) and strong profitability metrics (ROE 34.37%), but faces execution risks from recent net losses and high debt levels. Key catalysts include continued operational improvements and commodity price support, while risks involve debt management and margin pressures. Institutional sentiment appears constructive with recent position increases by major funds.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
